• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Status and Development Trend of Evaluation of Post-Marketing Traditional Chinese Medicines in China

    2020-12-29 06:51:39WEIRuili魏瑞麗WANGZhifei王志飛XIEYanming謝雁鳴
    關(guān)鍵詞:雁鳴瑞麗

    WEI Rui-li (魏瑞麗), WANG Zhi-fei (王志飛), XIE Yan-ming (謝雁鳴)

    ( Institute of Basic Research on Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China)

    ABSTRACT Evaluation of traditional Chinese medicines after the market has achieved fruitful results after years of development. The real-world research concept has been first proposed by Chief Researcher Xie Yanming in 2010 and to 2020 with the approval of the National Medical Products Administration to use real-world evidence to support drug development and review in 2020. Real-world data application and transformation continue to cause heated discussions in the industry. Real-world research concepts have been added new motivation into the evaluation of Chinese medicines after they are marketed. The development of the Chinese patent medicine industry is facing unprecedented opportunities and challenges.

    KEYWORDS Evaluation of traditional Chinese medicines after marketing; Real world research; Clinical safety evaluation; Pharmacovigilance

    Post-marketing evaluation is an important part of the drug life cycle and can make up for the limitations of pre-marketing evaluation. The scope of evaluation of traditional Chinese medicines after marketing is similar to that of chemical drugs,which is to evaluate the safety, effectiveness,pharmacoeconomics, etc. of a wide range of people in the actual clinical application of Chinese medicines that have been approved for marketing in accordance with relevant national regulations and promote the clinical rationality of traditional Chinese medicines. The use of drugs provides a basis for the risk and benefit assessment of traditional Chinese medicine and the national drug supervision work.

    STATUS AND DEVELOPMENT IN THE PAST 10 YEARS IN CHINA

    1. Evaluation of traditional Chinese medicines after they have been on the market has developed rapidly in the past 10 years and has been highly valued in China.

    1.1 At the national level, relevant policies and regulations are constantly improving

    China's post-marketing evaluation work stipulated that "evaluate drugs that have been approved for production" in the "Drug Administration Law of the People's Republic of China" (hereinafter referred to as "Drug Administration Law") issued in 2001; in 2007, The "Administrative Measures for Drug Registration" issued by the National Food and Drug Administration (SFDA) also stipulates that phase IV clinical trials are not carried out as required, and adverse drug reaction monitoring or evaluation, drugs will not be re-registered;On September 29, 2010, the SFDA issued the"Notice on Printing and Distributing 7 Technical Guidelines for Re-evaluation of the Production Process Evaluation of the Safety of Traditional Chinese Medicine Injections", including production process, quality control, non-clinical research,clinical research, risk control, The seven aspects of risk benefit evaluation and risk management provide guidance on how to carry out post-marketing evaluation, which greatly promotes the standardized and orderly development of post-market evaluation in China. At present, the evaluation of etraditional Chinese medicines after the market has become a scale, and the varieties with great development potential, large sales volume and better profit will be re-evaluated after the market; the "Adverse Drug Reaction Report and Monitoring Management Measures" issued by the Ministry of Health in 2011.It is stipulated that drug manufacturers must set up full-time institutions and full-time personnel to monitor adverse drug reactions, submit periodic safety update reports, fail to establish adverse drug reaction reports and monitoring management systems in accordance with regulations, and have no specialized agencies or full-time personnel responsible for adverse drug reaction reports in their units and monitoring work, failing to submit regular safety update reports in accordance with the requirements, will be given a warning, ordered to correct within a time limit, and fined. Since then,the National Adverse Drug Reaction Monitoring Center has issued the "Guidelines for Key Drug Monitoring" and "Guidelines for the Inspection of Adverse Drug Reaction Reports and Monitoring of Manufacturers" to guide enterprises to play the main role of normalized monitoring[1]. In June 2018,the Center for Drug Evaluation of the National Medical Products Administration (NMPA) publicly solicited opinions on the "General Considerations for the Clinical Research of Syndrome-based TCM New Drugs". In November of the same year, the National Medical Products Administration issued the "Technical Guidelines for Clinical Research of Syndrome-based TCM Drugs" "For the development,effectiveness, and safety evaluation of clinical trials of new Chinese medicines based on syndromes, the principled requirements are put forward with regard to the special considerations of traditional Chinese medicine, and the technical evaluation system of the characteristics of traditional Chinese medicine is continuously improved and promoted[2]. In 2019, the Twelfth Session of the Standing Committee of the 13th National People's Congress voted and passed the newly revised "Drug Administration Law", which specifically sets up Chapter 3 "Drug Marketing Authorization Holders", and the conditions,rights, obligations, and responsibilities have been comprehensively and systematically stipulated,and the main responsibility for the entire life cycle of the drug is assumed; Chapter 7 "Post-marketing Management of Drugs" puts forward specific requirements for post-marketing research and risk management of drugs[3]. On July 30, 2020, NMPA issued the "Opinions on Further Strengthening the Adverse Drug Reaction Monitoring and Evaluation System and Capacity Building", requesting to further strengthen the construction of adverse drug reaction monitoring and evaluation institutions and speed up the improvement of the adverse drug reaction monitoring and evaluation system, create a highef ficiency national adverse drug reaction monitoring information system, research and explore new methods of post-marketing drug safety monitoring and evaluation, guide and urge holders to implement the main responsibility for drug safety, and adhere to and consolidate the work mechanism of adverse drug reaction reporting in medical institutions[4].

    1.2 At the academic level, evaluation of Chinese medicines after the market has established a standardized method and technical system for the evaluation of Chinese medicines.

    With the expansion of the clinical application of traditional Chinese medicine injections and the increase in sales, based on the design,measurement and evaluation methods, the introduction of foreign advanced research concepts and technical methods has formulated the "Guidelines for Clinical Safety Evaluation of Chinese Medicine Injections"[5]. With reference to the pharmacoeconomics guidelines of various countries,combined with the particularity of traditional Chinese medicines, the "Technical Specifications for Post-Marketing Pharmacoeconomic Evaluation of Chinese Medicines"[6]was formulated to make the pharmacoeconomic evaluation process and results of Chinese patent medicines more scienti fic and reasonable. For the centralized monitoring of hospitals, the "Technical Speci fications for Centralized Monitoring of Traditional Chinese Medicines after the Market" and related reporting specifications[7]guide the large-sample, observational hospital centralized monitoring program and the use of nested casecontrol design on the characteristics and mechanisms of allergic reactions conduct in-depth research design, implementation, and reporting. In addition,post-market safety signal detection methods have also been explored and practiced, such as early warning technology for spontaneous reporting of adverse reactions and data analysis methods based on propensity scores.

    1.3 At present, there are still some problems in evaluation after the market of Chinese medicine

    The evaluation of Chinese medicines after the market is based on the combination of activity and passivity, scienti fic and feasibility, representativeness and authenticity, avoiding repeated evaluations,following the principles of medical ethics and embodying the characteristics of traditional Chinese medicine, and focusing on the safety evaluation of traditional Chinese medicine, evaluation of effectiveness of traditional Chinese medicine,economic evaluation of traditional Chinese medicine,and evaluation of combined use of traditional Chinese and western medicine[8]. At the same time,there are still some problems: (1) The enterprise is not very active. Companies are advancing under the impetus of policies, focusing on immediate bene fits and ignoring long-term plans. Some companies carry out post-marketing research in order to apply for entry into the medical insurance, basic medicine or China Insurance catalog, and the research stops once the application is completed. This approach is undoubtedly wrong. Enterprises must establish a long-term early warning mechanism,set up a special organization, assign a dedicated person to be responsible, and carry out normalized monitoring. (2) The credibility of the evaluation evidence is insufficient, and a market mechanism must be introduced and a third-party evaluation system established. The evaluation of traditional Chinese medicine after the market is in the process of subject differentiation and development towards professionalism. The evidence of evaluation is gradually accepted by the government, enterprises,medical staff and patients, and it has gradually become an important basis for decision-making.Whether the evidence of evaluation is true, objective and affects all aspects of medical and health. A team of high-level evaluation talents and professional evaluation agencies build a third-party evaluation system in accordance with market operating rules to improve the quality of re-evaluation evidence.(3) The effectiveness lacks high-quality evidencebased evidence, and the research on the mechanism of adverse reactions is not clear. The re-evaluation is based on human biological samples to study the ef ficacy and adverse reaction mechanism of human medication in the real world. Mechanism research needs to go further to clarify the mechanism and target of its clinical efficacy or adverse reactions,especially to study the mechanism of efficacy and adverse reactions of drugs in different populations,different comorbidities and combination medications.This is different from animal experiments conducted before the market. (4) The bene fit or risk reduction of the combination medication for patients is not clear. With the changes in the disease spectrum,more and more complex diseases such as coronary heart disease and tumors. In the actual medical environment, it is difficult to use one drug to block the multiple targets of the disease and achieve all therapeutic purposes. Therefore, combination drugs are widely available, especially the combined application of Chinese and Western medicine is becoming more common. However, whether the combination medication can really bring bene fits to patients or reduce the risk, will it "enhance ef ficiency and reduce toxicity" as predicted by theory, and further, if it can increase efficiency and reduce toxicity, what is the mechanism? Post-marketing research is to focus on this major and universal clinical problem and conduct research to produce scienti fic, evidence-based clinical evidence.

    STATUS ON THE EVALUATION IN RELEVENT FIELDS IN EUROPE AND AMERICA

    2. The evaluation of relevant policies,regulations and methods of drug after the market are basically mature in foreign countries, but the development is slow

    Developed countries represented by European countries, Japan, and the United States have conducted sufficient research on the effectiveness of drugs before they are marketed, and expand the population of drug users after they are marketed.Therefore, special attention is paid to re-evaluation of drug safety.

    The post-marketing evaluation work in the EU has been at the forefront. In July 2012, the EU implemented new pharmacovigilance regulations. In order to better promote the speci fic implementation of the new regulations, the European Medicines Agency has formulated the Good Pharmacovigilance Practices (GVP) as a new guideline for pharmacovigilance work in the European Union,replacing Volume 9A of the European Medicines Administration Act Part of "Pharmaceutical Police Ring South of Pharmaceutical Products for Human Use"[9]. The EU's pharmacovigilance consists of a series of interconnected processes, and the main pharmacovigilance processes are presented in the form of independent "modules" in the guidelines.GVP includes a total of 16 modules, covering the main aspects of pharmacovigilance, and has been formulated.

    In December 2016, the US Congress promulgated the "21st Century Cure Act", requiring the U.S. Food and Drug Administration (FDA) to include Real-World Evidence (RWE) in medical product review and supervision procedures. Since then, the FDA has successively issued statements and issued guidelines explaining the definition and characteristics of RWE, regulating the generation and application of RWE, and taking "giving full play to the role of RWE in review and regulatory decisionmaking" as its primary strategic focus. On December 6, 2018, the FDA announced the "Framework for FDA's Real-World Evidence Program" (Framework for FDA's Real-World Evidence Program), which provides a relatively clear roadmap for achieving RWE's goal of supporting review decisions.

    ON THE REAL WORLD RESARCH

    3. Introduce foreign advanced technology and methods, and continuously improve the technical system of evaluation methods for traditional Chinese medicines with traditional Chinese medicine characteristics.

    Traditional Chinese medicine is different from chemical medicine. Most proprietary Chinese medicines are compound prescriptions. Syndrome type Chinese medicines are very common.Syndrome differentiation and treatment and holistic view are the core of Chinese medicine theory.The particularity of Chinese medicines determines that the evaluation of Chinese medicines after the market cannot be copied abroad, and the market of Chinese medicines is constantly improved. Then evaluate the method and technical system to make it conform to the characteristics of traditional Chinese medicine. Real-world research is in line with the basic characteristics of the overall concept of TCM and syndrome differentiation and treatment. It will play an important role in the field of TCM clinical research and will occupy an important position in drug development and approval; the clinical effect and safety evaluation of drugs after the market will play a major role.

    Real-world research based on big data is suitable for post-market evaluation of Chinese medicines, and the concepts of the two are similar.The research of traditional Chinese medicine is fundamentally real world research. Traditional Chinese medicine rarely conducts randomized controlled trials under "ideal" conditions under strict conditions. It emphasizes that theories come from the clinic to the clinic, and more methods of induction are used to discover patterns in practice, and in practice verify the law, improve awareness and raise awareness. Real-world research originated from practical randomized controlled trials, emphasizing compliance with the reality of clinical medical treatment, non-random selection of treatment measures based on the actual condition and willingness of patients, and long-term, large-sample clinical observations to evaluate the clinical value of diagnosis and treatment measures and discover medicine laws, gain new knowledge. In addition, the characteristics of TCM syndrome differentiation and treatment and individual diagnosis and treatment emphasize the consideration of personal physique,psychology, social status, religious beliefs, personal wishes and other information, which can be fully implemented and exerted only under real-world conditions.

    Post-marketing evaluation involves a wide range of areas, and different evaluation methods are often used according to different evaluation purposes. No matter which evaluation method has its advantages and limitations. Therefore,integrate drug epidemiology, phase IV clinical trial data, passive monitoring data, active monitoring data, medical data and literature data, and use big data thinking to fully consider the timing and complementarity between the data, and carry out multiple perspectives, multi-level and comprehensive analysis.

    4. The development trend of evaluation after the market of Chinese medicine

    In recent years, national drug research and development policies and regulations have been continuously improved. Post-marketing evaluation research of traditional Chinese medicines revolves around clinical epidemiology and evidencebased medicine methodology, clinical research of syndrome-type new Chinese medicines,formulation of clinical practice guidelines and expert consensus, and real-world research design and data analysis paths, traditional Chinese medicine pharmacovigilance and risk and bene fit assessment of traditional Chinese medicine, implementation of scienti fic and traditional Chinese medicine evidence transformation, national medical decision-making,etc. continue to develop.

    4.1 Real-world research design and data analysis

    From the publication of the first domestic realworld research paper "Real-World Research: New Ideas for the Evaluation of the Effect of Traditional Chinese Medicine Interventions"[10]in 2010 to 2020,the National Medical Products Administration issued the "Guidelines for Real-World Evidence Supporting Drug Development and Evaluation" Principles(Trial)"[11], the research design, data analysis and application of real-world research continue to deepen.

    Real-world research belongs to the category of effect research, and has certain characteristics in common with other effect research. However,real-world research is used in the selection of the research population, the size of the sample, the application of randomness and control, the time point of evaluation and the determination of indicators,Data collection and statistical analysis have their own characteristics, which can complement RCT[12].In many cases, real-world research based on big data cannot control the quality of the data from the source, and can only achieve the data requirements of the research through data processing. For example, in large-scale prospective observational studies, data can be carried out through clinical research data management methods such as timely filling in a large amount of research data, accurate entry, computer-assisted manual review and proofreading, question and answer correction, and data blind review and lock-in, quality control. Realworld research based on the hospital information system (HIS) data, as an observational clinical trial,its data is essentially forward-looking data, and data quality control runs through the entire research including the research planning stage, the research process and the research end stage, including multiple data quality. The control link can greatly improve the quality of the HIS data through data quality control measures and the HIS optimization,thereby increasing the scientific nature of the research results.

    It is foreseeable that the application of realworld research is indispensable, but it also faces many challenges, such as the timeliness of data collection, data collection costs, data quality,handling of missing data and any bias in the data. In China, the volume of real-world data is large but the degree of standardization is low. The HIS of medical service institutions operates independently, and there is no national disease database. In addition,industry standards have not been established in real-world research methodology, and research is uneven. It is urgent for stakeholders to improve their understanding and investment in realworld research. A good project supervision and management mechanism will play a key role in research quality[13].

    4.2 Chinese medicine pharmacovigilance and risk and bene fit assessment of Chinese medicine

    Traditional Chinese medicine pharmacovigilance thought (compatibility, dose and treatment control,toxicity classification and poisoning rescue, etc.)attaches great importance to the safe use of Chinese medicine. With the changes of the times, it incorporates new connotations. Chinese medicine pharmacovigilance includes the theory of clinical safe use of traditional Chinese medicine and traditional Chinese medicine. Adverse reaction theory, traditional Chinese medicine toxicology and other academic content, safety monitoring and evaluation of traditional Chinese medicine before and after marketing, basic research on traditional Chinese medicine safety, discovery, evaluation,awareness and prevention of clinical safety issues of traditional Chinese medicine, and rational use of medicine guidance and publicity activities.

    At present, China's pharmacovigilance system highlights some problems: (1) The organizational system is not perfect, such as the large gaps in ADR monitoring institutions at all levels in information construction, expert teams, operating mechanisms,and funding guarantees; some cities and counties with poor drugs response agencies are attached to drug control institutes, information centers, etc., which are prone to unclear division of labor or overlapping functions; (2) The awareness of ADR reports is insufficient, such as poor initiative awareness, low quality of reports, low information utilization, and poor professional background of pharmacovigilance personnel; (3) Information transmission is not smooth, such as the uneven development level of pharmacovigilance in various regions and lack of communication; (4) The characteristics of traditional Chinese medicine are insufficient, such as the lack of pharmacological effects, adverse reactions,contraindications and other modern research content in many Chinese patent medicine instructions.

    Therefore, it is necessary to improve the traditional Chinese medicine pharmacovigilance system, form a pharmacovigilance system that meets the national conditions and has traditional Chinese medicine characteristics, enhance the concept of pharmacovigilance, formulate complete laws and regulations, improve organizational structure, strengthen the main body status of enterprises, give play to the role of medical institutions, and strengthen publicity training and education, increase supervision and punishment,establish a systematic and standard Chinese medicine application and evaluation system, and carry out post-marketing safety evaluation and risk management research of Chinese medicine[14].

    4.3 Implement scienti fic and traditional Chinese medicine evidence transformation

    From evidence to practice, there is a gap between ideal and reality. Ideally, medical information can be transformed into high-quality evidence, and high-quality evidence will be transformed into safe and effective clinical practice.Clinical professionals at all levels understand and master the use of high-quality evidence in the shortest possible time. The reality is that only a small part of medical information is converted into high-quality evidence, and high-quality evidence will be restricted by various factors in the process of converting it into clinical practice (including the available medical conditions, the level of professional and technical personnel, and the completeness of supporting services), clinical professionals may experience diminishing information at each lower level, and the wider the spread, the longer the cycle.In this context, the implementation of science came into being. The National Institutes of Health (NIH)defines implementation science as the study of methods used to integrate scientific findings and evidence into health service policies and practices.The core of implementing science is to fill the gaps in scientific research and clinical practice, and to introduce effective medical care interventions into clinical practice.

    The implementation of the scienti fic evaluation framework includes population coverage,intervention effects, institutional application,practical implementation and effect maintenance. To implement scienti fic common research designs, you can choose the intervention to be implemented, and select the corresponding design in combination with the scenario to be implemented, such as stepped mosaic cluster randomized controlled experiments,adaptive design, and a combination of qualitative and quantitative hybrid methods[15].

    Based on the current status quo that there is a large amount of clinical evidence in the field of Chinese medicine, and the national policy strongly supports the development of Chinese medicine to play a role in the health of the people, it is necessary to implement science in the field of Chinese medicine. Using evidence-based methodology,develop a set of strategies to promote the implementation of evidence-based practice, evaluate the effects before and after the implementation of the strategy, and finally realize the transformation of scienti fic research evidence into clinical practice[16].

    4.4 Pharmacoeconomic evaluation of traditional Chinese medicine and evidence-based medical decision-making

    Pharmacoeconomics evaluation can seek the best balance between drug resources and consumption and the improvement of health conditions, including disease burden, drug prescription management, drug pricing, national drug policies, and essential drug lists. The new version of the National Drug Insurance Catalogue released in 2019 accounted for half of the number of Chinese medicines, and 101 Chinese patent medicines were newly transferred[17]. The state vigorously supports the development of traditional Chinese medicine, continuously deepens the reform of the medical security system, establishes a dynamic adjustment mechanism for the drug catalog, and advances the reform of procurement methods, price negotiations, third-party payments,and centralized procurement. The success or failure of the re-evaluation of traditional Chinese medicine after the market is directly related to the value of the product and indirectly related to the company's product portfolio strategy and future development.Therefore, pharmaceutical companies need to make overall planning for the re-evaluation of products after the launch of the product from a strategic perspective, in order to achieve the maximization of corporate and social bene fits and the optimization of resource allocation.

    猜你喜歡
    雁鳴瑞麗
    情未了
    腎結(jié)石圍術(shù)期針對(duì)性護(hù)理應(yīng)用
    Clinical Study on the Treatment Efficacy of Cerebral Hemorrhage with Xingnaojing Injection in Real World
    Local Existence and Global Nonexistence Theorems for a Viscous Damped Quasi-Linear Wave Equations
    Study on Early Warning Signals of Report on Adverse Reactions of Spontaneous Reporting System of Runzao Zhiyang Capsule
    Enlightenment from WHO Pharmacovigilance in Construction of Chinese Materia Medica Pharmacovigilance System
    雁鳴湖納豆系列產(chǎn)品 款款熱銷
    傾聽雁鳴湖畔的人大足音
    《瑞麗時(shí)尚先鋒》將???明年起轉(zhuǎn)型做電商
    傳媒(2015年23期)2015-03-19 03:01:25
    《瑞麗》
    91字幕亚洲| 黑人猛操日本美女一级片| 午夜福利在线观看吧| 日本黄色日本黄色录像| 国产xxxxx性猛交| 婷婷精品国产亚洲av在线| 国产精品国产高清国产av| 欧美精品亚洲一区二区| 日韩免费高清中文字幕av| 欧美性长视频在线观看| 精品一区二区三卡| 中文字幕另类日韩欧美亚洲嫩草| 91麻豆av在线| 欧美性长视频在线观看| 精品人妻在线不人妻| 少妇裸体淫交视频免费看高清 | 国产伦一二天堂av在线观看| 色在线成人网| 大陆偷拍与自拍| 18禁黄网站禁片午夜丰满| 日韩大尺度精品在线看网址 | 亚洲av美国av| 一区在线观看完整版| 国产在线精品亚洲第一网站| 黄网站色视频无遮挡免费观看| 少妇被粗大的猛进出69影院| 老鸭窝网址在线观看| 精品日产1卡2卡| 国产免费男女视频| 国产成人系列免费观看| 亚洲黑人精品在线| 一级片'在线观看视频| 首页视频小说图片口味搜索| 国产成人欧美| 777久久人妻少妇嫩草av网站| 午夜激情av网站| 亚洲av成人不卡在线观看播放网| 日韩欧美一区视频在线观看| 不卡一级毛片| 黄网站色视频无遮挡免费观看| 激情在线观看视频在线高清| 好看av亚洲va欧美ⅴa在| 精品卡一卡二卡四卡免费| 亚洲专区字幕在线| 免费日韩欧美在线观看| 亚洲熟女毛片儿| 欧美乱色亚洲激情| 香蕉丝袜av| 性色av乱码一区二区三区2| 51午夜福利影视在线观看| 日日干狠狠操夜夜爽| 亚洲欧美一区二区三区黑人| 亚洲黑人精品在线| 99热国产这里只有精品6| 成年人免费黄色播放视频| 精品久久久久久久毛片微露脸| 久久久国产精品麻豆| 免费人成视频x8x8入口观看| 欧美成狂野欧美在线观看| 国产又爽黄色视频| 亚洲成人精品中文字幕电影 | 巨乳人妻的诱惑在线观看| 国产精品免费一区二区三区在线| 国产一区二区在线av高清观看| 免费看十八禁软件| 香蕉国产在线看| 欧美日韩亚洲国产一区二区在线观看| 欧美日韩亚洲国产一区二区在线观看| 热99re8久久精品国产| 久久久国产成人免费| 99久久精品国产亚洲精品| 高清av免费在线| 亚洲国产精品合色在线| 亚洲精品一二三| 久久九九热精品免费| 淫妇啪啪啪对白视频| 丝袜在线中文字幕| 亚洲人成77777在线视频| 亚洲欧美激情综合另类| 日本黄色日本黄色录像| 欧美色视频一区免费| 久久 成人 亚洲| 成人国产一区最新在线观看| 51午夜福利影视在线观看| 成熟少妇高潮喷水视频| 妹子高潮喷水视频| 午夜福利免费观看在线| www国产在线视频色| 老司机亚洲免费影院| 亚洲国产看品久久| a在线观看视频网站| 黄片播放在线免费| 亚洲av成人不卡在线观看播放网| 亚洲精品国产精品久久久不卡| 人人妻人人澡人人看| 热re99久久国产66热| 亚洲伊人色综图| 国产精品免费一区二区三区在线| 国产男靠女视频免费网站| 精品福利观看| 国产高清视频在线播放一区| 亚洲美女黄片视频| 亚洲成人国产一区在线观看| 一个人免费在线观看的高清视频| 欧美成狂野欧美在线观看| 日日爽夜夜爽网站| 亚洲伊人色综图| 久久香蕉国产精品| 精品国产乱码久久久久久男人| 97人妻天天添夜夜摸| 日本免费一区二区三区高清不卡 | 美女国产高潮福利片在线看| 亚洲精品成人av观看孕妇| 欧美亚洲日本最大视频资源| 午夜免费成人在线视频| 搡老岳熟女国产| 88av欧美| 久久久久久亚洲精品国产蜜桃av| 亚洲精品成人av观看孕妇| 99国产精品免费福利视频| 国产欧美日韩综合在线一区二区| 亚洲午夜精品一区,二区,三区| 一进一出好大好爽视频| 久久久精品国产亚洲av高清涩受| 午夜激情av网站| 亚洲,欧美精品.| 69精品国产乱码久久久| 久久久久国产精品人妻aⅴ院| 国产蜜桃级精品一区二区三区| 青草久久国产| 久久精品国产综合久久久| 天天影视国产精品| 成人黄色视频免费在线看| 精品卡一卡二卡四卡免费| 精品一区二区三卡| 一区在线观看完整版| 9191精品国产免费久久| 精品人妻在线不人妻| 国产av又大| 在线国产一区二区在线| 80岁老熟妇乱子伦牲交| 精品熟女少妇八av免费久了| 激情在线观看视频在线高清| 国产精品日韩av在线免费观看 | 欧美性长视频在线观看| 99精品欧美一区二区三区四区| 波多野结衣一区麻豆| 在线观看舔阴道视频| 男女下面进入的视频免费午夜 | 99在线人妻在线中文字幕| 日本撒尿小便嘘嘘汇集6| 久久久久国产精品人妻aⅴ院| 18禁国产床啪视频网站| 夜夜夜夜夜久久久久| 黄色毛片三级朝国网站| 在线国产一区二区在线| 真人一进一出gif抽搐免费| 可以免费在线观看a视频的电影网站| 天堂影院成人在线观看| 人人澡人人妻人| 激情在线观看视频在线高清| 999精品在线视频| 婷婷六月久久综合丁香| 99精品久久久久人妻精品| 成人永久免费在线观看视频| 黄片小视频在线播放| 久久久精品国产亚洲av高清涩受| 亚洲五月色婷婷综合| 成年人免费黄色播放视频| 首页视频小说图片口味搜索| 每晚都被弄得嗷嗷叫到高潮| 69av精品久久久久久| 人妻丰满熟妇av一区二区三区| 免费看a级黄色片| 亚洲国产欧美一区二区综合| 国产激情欧美一区二区| 日本 av在线| 后天国语完整版免费观看| 咕卡用的链子| 亚洲精品美女久久av网站| 狂野欧美激情性xxxx| 中文亚洲av片在线观看爽| 国产成人精品在线电影| 成人18禁高潮啪啪吃奶动态图| 人人妻,人人澡人人爽秒播| 亚洲精华国产精华精| 精品国内亚洲2022精品成人| 一区福利在线观看| av片东京热男人的天堂| 国产一区二区三区视频了| 99精国产麻豆久久婷婷| 人人妻人人添人人爽欧美一区卜| 在线观看免费视频网站a站| 久9热在线精品视频| 欧美 亚洲 国产 日韩一| 宅男免费午夜| av网站在线播放免费| 身体一侧抽搐| 亚洲黑人精品在线| 香蕉久久夜色| 亚洲视频免费观看视频| 婷婷丁香在线五月| 国产深夜福利视频在线观看| 久久精品91无色码中文字幕| 无限看片的www在线观看| 国产91精品成人一区二区三区| aaaaa片日本免费| 国产精品免费视频内射| 亚洲av电影在线进入| 夫妻午夜视频| 搡老岳熟女国产| 波多野结衣一区麻豆| 岛国在线观看网站| av在线天堂中文字幕 | 亚洲一区二区三区色噜噜 | 亚洲国产中文字幕在线视频| 亚洲欧美精品综合一区二区三区| 俄罗斯特黄特色一大片| 精品国内亚洲2022精品成人| 搡老岳熟女国产| 一区在线观看完整版| 欧美日韩瑟瑟在线播放| 亚洲精品国产精品久久久不卡| 亚洲精品国产一区二区精华液| 国产精品综合久久久久久久免费 | 久9热在线精品视频| 欧美不卡视频在线免费观看 | 激情在线观看视频在线高清| 99国产综合亚洲精品| 两个人看的免费小视频| 午夜a级毛片| 黄色片一级片一级黄色片| 亚洲欧美日韩另类电影网站| 亚洲欧美一区二区三区黑人| 午夜免费鲁丝| 亚洲全国av大片| 欧美日韩瑟瑟在线播放| 国产精品亚洲一级av第二区| 国产一卡二卡三卡精品| 欧美日韩视频精品一区| 99久久99久久久精品蜜桃| 国产男靠女视频免费网站| 99在线人妻在线中文字幕| 一区二区三区精品91| 中文字幕最新亚洲高清| 国产精品98久久久久久宅男小说| 国产黄a三级三级三级人| 亚洲精品国产一区二区精华液| 欧美+亚洲+日韩+国产| 视频在线观看一区二区三区| 色婷婷久久久亚洲欧美| 国产成人精品在线电影| 可以在线观看毛片的网站| 久久亚洲精品不卡| www国产在线视频色| 欧美一区二区精品小视频在线| 久久精品91无色码中文字幕| 欧美不卡视频在线免费观看 | 久久青草综合色| 在线观看免费视频网站a站| 很黄的视频免费| 精品一区二区三区视频在线观看免费 | 日韩人妻精品一区2区三区| 欧美日韩国产mv在线观看视频| 深夜精品福利| 国产aⅴ精品一区二区三区波| 天天躁狠狠躁夜夜躁狠狠躁| 桃色一区二区三区在线观看| 好男人电影高清在线观看| 麻豆av在线久日| 热99国产精品久久久久久7| videosex国产| 看免费av毛片| 亚洲成av片中文字幕在线观看| 国产亚洲欧美精品永久| 91成人精品电影| 久久久国产成人免费| 在线观看免费视频日本深夜| 一级片免费观看大全| 韩国av一区二区三区四区| 91精品三级在线观看| 国产精品永久免费网站| 亚洲国产看品久久| 大码成人一级视频| 欧美日本亚洲视频在线播放| 国产麻豆69| 国产一区二区三区视频了| 麻豆av在线久日| 色婷婷久久久亚洲欧美| 亚洲七黄色美女视频| netflix在线观看网站| 亚洲熟妇熟女久久| 精品一区二区三区四区五区乱码| av天堂久久9| 别揉我奶头~嗯~啊~动态视频| www.熟女人妻精品国产| 欧美日韩黄片免| 美女高潮到喷水免费观看| 国产区一区二久久| 欧美激情久久久久久爽电影 | 乱人伦中国视频| а√天堂www在线а√下载| 久久久国产一区二区| 身体一侧抽搐| 国产成人精品无人区| 国产亚洲精品综合一区在线观看 | 欧美国产精品va在线观看不卡| 一二三四社区在线视频社区8| 国产高清国产精品国产三级| av视频免费观看在线观看| 婷婷丁香在线五月| 国产又色又爽无遮挡免费看| 99久久综合精品五月天人人| 日韩 欧美 亚洲 中文字幕| 亚洲一区高清亚洲精品| av天堂在线播放| 一进一出抽搐动态| 91字幕亚洲| 别揉我奶头~嗯~啊~动态视频| 久久精品91蜜桃| 久久精品成人免费网站| 侵犯人妻中文字幕一二三四区| 欧美成人性av电影在线观看| 757午夜福利合集在线观看| 欧美日韩亚洲综合一区二区三区_| 国产成人免费无遮挡视频| 99精品欧美一区二区三区四区| 欧美大码av| 久热这里只有精品99| av网站在线播放免费| 丁香欧美五月| 校园春色视频在线观看| 国产主播在线观看一区二区| 午夜久久久在线观看| 国产xxxxx性猛交| 狂野欧美激情性xxxx| 国产亚洲精品第一综合不卡| 狂野欧美激情性xxxx| 久久人人精品亚洲av| 日本wwww免费看| 老熟妇仑乱视频hdxx| 男人操女人黄网站| 日韩免费av在线播放| 一级作爱视频免费观看| 大型黄色视频在线免费观看| 很黄的视频免费| 国产深夜福利视频在线观看| av片东京热男人的天堂| 亚洲欧美日韩无卡精品| 成熟少妇高潮喷水视频| 男女做爰动态图高潮gif福利片 | 精品卡一卡二卡四卡免费| videosex国产| 好看av亚洲va欧美ⅴa在| 嫩草影院精品99| 9191精品国产免费久久| 中文字幕人妻丝袜制服| 欧美精品啪啪一区二区三区| 久久99一区二区三区| www日本在线高清视频| 一夜夜www| 欧美国产精品va在线观看不卡| 久久久久久亚洲精品国产蜜桃av| 精品人妻1区二区| x7x7x7水蜜桃| 色在线成人网| 校园春色视频在线观看| 国产精品国产av在线观看| 久久久久精品国产欧美久久久| 久久精品国产亚洲av香蕉五月| 久久伊人香网站| 黄色女人牲交| 黑人欧美特级aaaaaa片| www.999成人在线观看| 精品久久久久久久久久免费视频 | 国产片内射在线| 免费av毛片视频| 国产av一区在线观看免费| 另类亚洲欧美激情| 午夜免费鲁丝| 午夜福利,免费看| 人人妻人人添人人爽欧美一区卜| 久久久久久久午夜电影 | 久久久久久久久久久久大奶| 一级a爱视频在线免费观看| 免费看十八禁软件| 激情视频va一区二区三区| 91国产中文字幕| 在线观看www视频免费| 欧美乱妇无乱码| 麻豆久久精品国产亚洲av | 精品一区二区三卡| 伦理电影免费视频| 91精品三级在线观看| 可以在线观看毛片的网站| 亚洲av日韩精品久久久久久密| 中文字幕高清在线视频| 国产伦人伦偷精品视频| 老熟妇乱子伦视频在线观看| 一区二区三区精品91| 老汉色∧v一级毛片| 99香蕉大伊视频| 亚洲 国产 在线| x7x7x7水蜜桃| 美女午夜性视频免费| 国产激情久久老熟女| 他把我摸到了高潮在线观看| 免费观看精品视频网站| 露出奶头的视频| 又黄又粗又硬又大视频| 国产精品久久久久久人妻精品电影| 亚洲精品一卡2卡三卡4卡5卡| 亚洲人成电影观看| 欧美日韩亚洲高清精品| 久久这里只有精品19| 久久国产乱子伦精品免费另类| 老司机福利观看| 久热这里只有精品99| 婷婷丁香在线五月| 午夜免费成人在线视频| 国产精品一区二区三区四区久久 | av天堂久久9| 在线视频色国产色| 老司机午夜十八禁免费视频| 国产精品一区二区精品视频观看| 国产黄a三级三级三级人| 高清av免费在线| 免费在线观看影片大全网站| 人成视频在线观看免费观看| 看黄色毛片网站| 欧美老熟妇乱子伦牲交| 欧美另类亚洲清纯唯美| 村上凉子中文字幕在线| 欧美日韩福利视频一区二区| 在线观看免费视频日本深夜| 亚洲黑人精品在线| 一本大道久久a久久精品| 亚洲熟妇中文字幕五十中出 | 国产真人三级小视频在线观看| 极品人妻少妇av视频| 久久久久久人人人人人| 黄片大片在线免费观看| 久久久久国产精品人妻aⅴ院| 亚洲性夜色夜夜综合| av国产精品久久久久影院| 国产一卡二卡三卡精品| 国产精品 欧美亚洲| 亚洲男人天堂网一区| 99国产精品99久久久久| 久久精品国产亚洲av高清一级| 97人妻天天添夜夜摸| 欧美乱妇无乱码| 亚洲av成人不卡在线观看播放网| 成人三级做爰电影| 日本精品一区二区三区蜜桃| 久久国产亚洲av麻豆专区| 国产亚洲精品久久久久5区| 日韩免费高清中文字幕av| 日本免费a在线| 变态另类成人亚洲欧美熟女 | 黄色毛片三级朝国网站| 性色av乱码一区二区三区2| av免费在线观看网站| 亚洲色图 男人天堂 中文字幕| 亚洲伊人色综图| 成人亚洲精品av一区二区 | 韩国av一区二区三区四区| 久久久久久久精品吃奶| 999精品在线视频| 日本撒尿小便嘘嘘汇集6| avwww免费| 亚洲在线自拍视频| 久久中文字幕人妻熟女| 一级黄色大片毛片| 99热国产这里只有精品6| 美女大奶头视频| 级片在线观看| 欧美日韩中文字幕国产精品一区二区三区 | 亚洲精品国产色婷婷电影| 国产欧美日韩精品亚洲av| 国产熟女xx| 国产精品久久久久久人妻精品电影| 亚洲精品在线美女| 国产亚洲欧美98| 黄色女人牲交| 热re99久久国产66热| 日韩av在线大香蕉| 欧美日韩亚洲高清精品| 欧美一级毛片孕妇| 99国产精品免费福利视频| 女人爽到高潮嗷嗷叫在线视频| 精品福利永久在线观看| 欧美亚洲日本最大视频资源| 欧美中文日本在线观看视频| 99热只有精品国产| 午夜福利影视在线免费观看| www.www免费av| 大型黄色视频在线免费观看| www.精华液| 国产一区二区三区综合在线观看| 热99国产精品久久久久久7| 青草久久国产| 亚洲国产毛片av蜜桃av| 亚洲情色 制服丝袜| 国产精品av久久久久免费| 亚洲欧美日韩另类电影网站| 很黄的视频免费| 国产av一区二区精品久久| 国产精品野战在线观看 | 久久婷婷成人综合色麻豆| 亚洲成国产人片在线观看| 欧美激情 高清一区二区三区| 欧美日韩国产mv在线观看视频| 中国美女看黄片| 伊人久久大香线蕉亚洲五| 亚洲精品国产一区二区精华液| 久久久水蜜桃国产精品网| www日本在线高清视频| 国产av又大| 国产精品久久久av美女十八| 黄色怎么调成土黄色| 日本免费a在线| 国产99白浆流出| 国产成人欧美在线观看| 精品国产美女av久久久久小说| 一区二区三区国产精品乱码| 亚洲五月天丁香| 日韩精品青青久久久久久| 黑人猛操日本美女一级片| 久久久久久大精品| 亚洲精品成人av观看孕妇| 精品久久久久久电影网| 国产91精品成人一区二区三区| 亚洲欧美一区二区三区久久| 午夜免费激情av| 午夜影院日韩av| 久久人人爽av亚洲精品天堂| 免费女性裸体啪啪无遮挡网站| 不卡一级毛片| 成熟少妇高潮喷水视频| av有码第一页| 久久国产精品影院| 亚洲欧美激情综合另类| 日韩欧美三级三区| 一本大道久久a久久精品| 制服诱惑二区| 精品一区二区三卡| 看片在线看免费视频| 中亚洲国语对白在线视频| 波多野结衣高清无吗| 亚洲精品国产色婷婷电影| 国产av精品麻豆| 久久精品91蜜桃| 老司机午夜福利在线观看视频| 桃红色精品国产亚洲av| 久久国产乱子伦精品免费另类| 夜夜躁狠狠躁天天躁| 亚洲一码二码三码区别大吗| 91字幕亚洲| 搡老乐熟女国产| 久久中文字幕人妻熟女| 国产一区二区三区视频了| 成人三级做爰电影| 久久精品人人爽人人爽视色| 变态另类成人亚洲欧美熟女 | 99国产精品一区二区三区| 国产熟女午夜一区二区三区| 国产精品香港三级国产av潘金莲| 黄色毛片三级朝国网站| 又大又爽又粗| 精品久久久久久,| 欧美最黄视频在线播放免费 | 国产精品久久久久成人av| 久久香蕉激情| 在线永久观看黄色视频| 在线观看舔阴道视频| 如日韩欧美国产精品一区二区三区| 国产又色又爽无遮挡免费看| 色综合婷婷激情| 国产成人精品无人区| 97碰自拍视频| 黑人欧美特级aaaaaa片| 69av精品久久久久久| 久久久久亚洲av毛片大全| 成人18禁高潮啪啪吃奶动态图| 亚洲av第一区精品v没综合| 18禁观看日本| 91大片在线观看| 在线看a的网站| 好男人电影高清在线观看| 国产aⅴ精品一区二区三区波| а√天堂www在线а√下载| 大型黄色视频在线免费观看| 最新美女视频免费是黄的| 最近最新中文字幕大全免费视频| 97碰自拍视频| 淫妇啪啪啪对白视频| 免费搜索国产男女视频| 国产三级在线视频| 黑人欧美特级aaaaaa片| 亚洲七黄色美女视频| 日韩欧美国产一区二区入口| 国产成人av激情在线播放| av网站免费在线观看视频| 女人高潮潮喷娇喘18禁视频| 免费观看精品视频网站| 久久精品成人免费网站| 亚洲第一av免费看| 在线国产一区二区在线| 香蕉国产在线看| 国产av一区二区精品久久| 欧美人与性动交α欧美软件| 黄色片一级片一级黄色片| 欧美黑人欧美精品刺激| 九色亚洲精品在线播放|